Strategic Global Distribution Agreement for PURA Series™ MCC

Nordic Bioproducts Group, a Finland-based scaleup, and Atlantic Chemicals Trading Group, a Hamburg-based distributor, have entered a strategic global distribution agreement for PURA Series™ Microcrystalline Cellulose (MCC). The cooperation aims to support the international market introduction of PURA Series™ MCC, that is sustainable produced by patented AaltoCell® technology.

Nordic Bioproducts Group – Finnish Scaleup Focused on Cellulose Innovation
Nordic Bioproducts Group is an innovative scaleup headquartered in Finland, specializing in the development of advanced cellulose-based materials. Leveraging Finland’s strong background in forestry, materials science, and bio-based technologies, Nordic Bioproducts Group has focused its research and development activities on improving conventional cellulose products.

The company owns a proprietary and patented AaltoCell® process that enables the production of a specialized form of Microcrystalline Cellulose with tailored material characteristics. Nordic Bioproducts Group combines scientific expertise with scalable production concepts, positioning itself as a technology-driven supplier of functional cellulose materials.

PURA Series™ MCC and Its Applications
Microcrystalline Cellulose is a purified, partially depolymerized cellulose derived from natural plant fibers and is widely used as a multifunctional ingredient in regulated and industrial applications.
The PURA Series™ MCC developed by Nordic Bioproducts Group is characterized by controlled particle morphology and consistent material properties, resulting in improved performance compared to conventional MCC grades.
Key product characteristics include:

• High bulk density, leading to significantly reduced volume requirements, particularly advantageous for capsule filling and high-throughput manufacturing
• Excellent and consistent flowability, supporting stable processing and reliable dosing compared to standard MCC qualities
• High purity, ultra-low nitrite levels and free from burnt particles or black spots, supporting quality-sensitive applications
• Production in Europe, enabling a transparent, reliable, and simplified supply chain

Operational and formulation benefits include:

• Reduced machine downtime, as stable flow properties and consistent quality help minimize processing interruptions and unplanned cleaning cycles
• Clean label formulation potential, as improved flow behavior allows manufacturers to reduce or eliminate additional flow aids, such as silicon dioxide, from ingredient declarations

Typical application areas include:

• Food and Nutraceuticals: carrier and filler for active ingredients, stabilizer, texturizer, and capsule formulations
• Pharmaceuticals: binder and filler for tablets and capsules with improved compressibility and process stability
• Cosmetics & Personal Care: natural exfoliant, stabilizer, absorbent and rheology-modifying agent
• Industrial and NRT Applications: functional additive for stabilization and rheology control

About ACT Group
ACT Group is an established trading company based in Hamburg, Germany, with 40 years of experience in the international distribution of raw materials and functional ingredients. The company provides comprehensive expertise in sales and logistics, including supply chain management and customer support in regulated and industrial markets.
Through this cooperation, ACT supports Nordic Bioproducts Group with the commercial and logistical know-how required to scale its PURA Series™ MCC.

“This partnership allows us to focus on further development of our PURA Series™ MCC range while relying on an experienced partner for international sales and logistics,” said Olli Kähkönen, CEO of Nordic Bioproducts Group. “ACT’s market knowledge and distribution capabilities provide a strong foundation for expansion into Europe and the US.”

“Nordic Bioproducts Group’s PURA Series™ MCC represents a technologically differentiated product with significant application potential,” said Matin Ghaffari, COO of ACT Group. “The agreement enables structured market access while supporting Nordic Bioproducts Group with established sales processes and logistics expertise.”

‍